Nasdaq Stockholm has today decided to admit the shares of Ascelia Pharma for trading on Nasdaq Stockholm’s Main Market with first day of trading being 13thof March 2019. The additional capital generated from the initial public offering allows Ascelia to fund its global Phase III program for its lead product Mangoral.
Prof. Hans Maier from BGM Associates had joined the company’s board of directors in 2017.
Full Press Release
Prof. Hans Maier from BGM Associates had joined the company’s board of directors in 2017.
Full Press Release
